Tevogen Bio Holdings Inc
Research Tevogen Bio Holdings Inc (TVGN) on Bullrun: market cap USD 29.66M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTVGN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 29.66M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 5.45M
- Free cash flow-USD 2.73M
Valuation Snapshot
latest market cap is USD 29.66M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 26.28M | -USD 12.39M | n/a | -8.08 | USD 0 | USD 7.50M | -USD 8.23M |
| FY2024 | USD 0 | -USD 13.73M | -USD 12.00M | n/a | -3.5 | USD 0 | USD 2.89M | -USD 6.67M |
| FY2023 | USD 0 | -USD 60.48M | -USD 8.30M | n/a | -2.44 | USD 0 | USD 95.42M | -USD 94.43M |
| FY2022 | n/a | USD 4.41M | n/a | n/a | n/a | USD 129.19K | USD 0 | -USD 33.95M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 29.66M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 66.54M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 183.33M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.76B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | n/a | 12912.5 | n/a | n/a |
About Tevogen Bio Holdings Inc
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tevogen Bio Holdings Inc's market cap?
Tevogen Bio Holdings Inc's market capitalization is USD 29.66M.
What does Tevogen Bio Holdings Inc do?
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.